• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiology >Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease
【24h】

Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease

机译：小剂量培高利特治疗对帕金森氏病患者心脏瓣膜的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions. OBJECTIVES: The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease. METHODS: One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 +/- 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 +/- 7 years).Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale. RESULTS: No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05). CONCLUSIONS: Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.
机译：背景：培高利特甲磺酸盐在美国和日本被广泛用于治疗帕金森氏病，但是美国（通常大于1.5毫克/天）和日本（通常小于1.5毫克/天）的维持剂量明显不同。尽管来自美国的几份报告表明二尖瓣，主动脉和三尖瓣病变是由培高利特引起的，但尚不清楚低剂量培高利特疗法是否会引起此类瓣膜病变。目的：在日本帕金森氏病患者中研究了小剂量培高利特治疗对心脏瓣膜的影响。方法：本研究纳入了已被批准接受本研究方案的115例帕金森氏病患者。 40例接受低剂量培高利特治疗（0.05-1.5 mg /天，持续2-115个月），并被纳入培高利德组（平均年龄71 +/- 6岁）。其他44例患者未接受麦角衍生的多巴胺受体激动剂，并且32例患者作为年龄匹配的对照（平均年龄71 +/- 7岁）。两组患者均接受了超声心动图检查，以发现心脏瓣膜的器质性病变，例如增厚小叶的瓣膜，环状钙化，瓣膜运动受限和瓣膜扩张以及瓣膜反流在4分制上大于2 +。结果：培高利特组与对照组的主动脉，二尖瓣和肺动脉瓣病变的发生率没有显着差异。尽管在三尖瓣中未发现器质性病变，但培高利特组三尖瓣关闭不全的发生率明显高于对照组（p <0.05）。结论：虽然低剂量的培高利特小于1.5 mg / day不会对左侧瓣膜造成严重损害，但可能引起三尖瓣关闭不全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号